^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Repatha (evolocumab)

    i
    Other names: AMG 145, AMG-145, AMG145
    Company:
    Amgen, Astellas, Dr. Reddy’s
    Drug class:
    PCSK9 inhibitor
    Related drugs:
    25d
    Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose. (clinicaltrials.gov)
    P1, N=400, Recruiting, Amgen | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Repatha (evolocumab)
    1m
    Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose (clinicaltrials.gov)
    P1, N=405, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Repatha (evolocumab)
    2ms
    Assessing the Risk of Drug-Induced Influenza-Like Illness: A Disproportionality Analysis of Two Decades of FAERS Data (2004-2025). (PubMed, Curr Drug Saf)
    This first comprehensive FAERS study identifies key drugs associated with ILI, including interferon β-1a, evolocumab, ofatumumab, interferon β-1b, and zoledronic acid. Clinical monitoring for drug-induced ILI is essential to enhance medication safety.
    Journal
    |
    IFNB1 (Interferon Beta 1)
    |
    Arzerra (ofatumumab) • zoledronic acid • Repatha (evolocumab)
    2ms
    CAPER-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS (clinicaltrials.gov)
    P4, N=233, Recruiting, West China Hospital
    New P4 trial
    |
    Repatha (evolocumab)
    2ms
    Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov)
    P1/2, N=314, Terminated, Hoffmann-La Roche | Completed --> Terminated; Study was closed early as the sponsor decided not to continue development of certain treatment combinations.
    Trial termination
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Repatha (evolocumab) • camonsertib (RP-3500) • cibisatamab (RG7802) • ciforadenant (CPI-444) • zanzalintinib (XL092)
    3ms
    TOP2101: A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC (clinicaltrials.gov)
    P2, N=19, Terminated, Eziafa Oduah, MD, PhD, MPH | N=38 --> 19 | Active, not recruiting --> Terminated; Slow enrollment.
    Enrollment change • Trial termination
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Repatha (evolocumab)
    3ms
    EPOCH-LYSIS: Evaluation Study of Early Administration of Evolocumab After Thrombolysis in Patients With Atherosclerotic Acute Ischemic Stroke (clinicaltrials.gov)
    P4, N=132, Completed, The Affiliated Hospital of Xuzhou Medical University | Recruiting --> Completed | Trial completion date: Aug 2026 --> Apr 2026 | Trial primary completion date: Aug 2026 --> Apr 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Repatha (evolocumab)
    3ms
    Efficacy and Safety of Evolocumab as a Radiosensitizer in Locally Advanced Lung Cancer: A Single-Center, Open-Label, Randomized Controlled Trial (ChiCTR2600121237)
    P=N/A, N=82, Xi'an Jiaotong University Second Affiliated Hospital; Xi'an Jiaotong University Second Affiliated Hospital
    New trial
    |
    Repatha (evolocumab)
    3ms
    Early Initiation of Evolocumab in Acute Coronary Syndrome: A Real-World Comparative Study of Lipid Goal Attainment and Inflammatory Modulation (ChiCTR2600118799)
    P=N/A, N=204, Completed, Shanghai Pudong New Area Gongli Hospital; Shanghai Pudong New Area Gongli Hospital
    New trial • Real-world evidence
    |
    Repatha (evolocumab)
    3ms
    Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose. (clinicaltrials.gov)
    P1, N=400, Not yet recruiting, Amgen
    New P1 trial
    |
    Repatha (evolocumab)
    3ms
    VICTORION-LEAP: A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab (clinicaltrials.gov)
    P=N/A, N=5995, Not yet recruiting, Novartis Pharmaceuticals
    New trial • Real-world evidence
    |
    Repatha (evolocumab) • Praluent (alirocumab)
    3ms
    Mechanistic Clinical Trial of PCSK9 Inhibition for AAA (clinicaltrials.gov)
    P1, N=44, Not yet recruiting, University of Pennsylvania | Trial completion date: Feb 2028 --> Feb 2029 | Trial primary completion date: Nov 2027 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    Repatha (evolocumab)